Completed PHASE2 INTERVENTIONAL 2-arm NCT01000051

Eltrombopag for Post Transplant Thrombocytopenia

Sponsor: M.D. Anderson Cancer Center

Updated 12 times since 2017 Last updated: Sep 6, 2023 Started: Feb 17, 2010 Primary completion: Apr 4, 2018 Completion: Apr 4, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Thrombocytopenia, this trial is completed. The trial is conducted by M.D. Anderson Cancer Center and has accumulated 12 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

12 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Oct 2023 — Jul 2024 [monthly]

Completed PHASE2
Mar 2023 — Oct 2023 [monthly]

Completed PHASE2
Jan 2021 — Mar 2023 [monthly]

Completed PHASE2

▶ Show 7 earlier versions

Aug 2019 — Jan 2021 [monthly]

Completed PHASE2
Jun 2019 — Aug 2019 [monthly]

Completed PHASE2
Jun 2018 — Jun 2019 [monthly]

Completed PHASE2
May 2018 — Jun 2018 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Jun 2017 — May 2018 [monthly]

Active Not Recruiting PHASE2
Feb 2017 — Jun 2017 [monthly]

Active Not Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Feb 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States